New Delhi: The Centre’s decision to cap trade margins on 137 non-scheduled anti-cancer drugs has reduced the maximum retail prices (MRPs) of 484 of 643 listed medicine packs, but left nearly one in four packs unchanged, raising questions about how much relief the measure will bring to cancer patients, an analysis of National Pharmaceutical Pricing Authority (NPPA) data has found
New Delhi: The Centre’s decision to cap trade margins on 137 non-scheduled anti-cancer drugs has reduced the maximum retail prices (MRPs) of 484 of 643 listed medicine packs, but left nearly one in four packs unchanged, raising questions about how much relief the measure will bring to cancer patients, an analysis of National Pharmaceutical Pricing Authority (NPPA) data has found
<iframe src="https://hindustansphere.com/embed/cluster/97b5e67107269d4be4d3dae5fc3c7114fc88c0f6" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Nearly 1 in 4 cancer drug prices unchanged: Data"></iframe>
